panobinostat

Also known as LBH589, Farydak®, LBH-589, LBH 589, (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).

Research

1,263 papers

Panobinostat: first global approval.Drugs · 2015
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2021
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.Cell · 2024
Panobinostat for the management of multiple myeloma.Future oncology (London, England) · 2017
Panobinostat for the Treatment of Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015

via PubMed

Wikidata facts

Mass: 349.179

Show 5 more facts

chemical formula: C₂₁H₂₃N₃O₂
canonical SMILES: CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO
isomeric SMILES: CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
World Health Organisation international non-proprietary name: panobinostat
Commons category: Panobinostat

Sources (5)

via Wikidata · CC0

~6 min read

Article

9 sections

Contents

Medical uses
Contraindications
Side effects
Pharmacology
Mechanism of action
Pharmacokinetics
Clinical trials
Preclinical studies
References

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 455315413 | image = Panobinostat.svg | image_class = skin-invert-image | width = 275 | alt =